ArticleClinical oral investigations2026
Apical bone coverage and implant survival after lateral sinus floor elevation: a retrospective study.
Article in Clinical oral investigations, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study evaluated the impact of apical bone height (ABH) on implant survival after lateral sinus floor elevation (LSFE) with simultaneous implantation, controlling for confounding factors.
methodsA retrospective cohort of 195 implants was analyzed. ABH was measured immediately postoperatively (T1), at 6 months (T2), and at ≥ 2 years (T3), and stratified as ≤ 2 mm or > 2 mm. Survival was assessed using Kaplan-Meier curves and multivariable Cox regression, adjusting for demographic, surgical, behavior, and anatomic variables.
resultsABH and endo-sinus bone gain significantly declined from T1 to T2 (p < 0.001) and continued to decrease at T3 (p < 0.001). Multivariable analysis identified ABH > 2 mm as a significant independent protective factor for implant survival at all timepoints (T1: HR = 0.100, p = 0.035; T2: HR = 0.039, p < 0.001; T3: HR = 0.040, p = 0.007). Conversely, the magnitude of ABH change did not significantly influence survival. Kaplan-Meier analysis showed markedly lower cumulative survival rates (CSRs) for ABH ≤ 2 mm (log-rank p < 0.001). At 40 months, CSRs were 20.0% at T1, 37.5% at T2, and 46.1% at T3. When ABH was excluded from the model, smoking emerged as an independent predictor (HR = 3.648, p = 0.023), while sex, age, and implant site were not significant.
conclusionsABH decreases significantly within 6 months after LSFE and continues to decline thereafter. Critically, ABH ≤ 2 mm is a consistent and powerful predictor of implant failure, underscoring its importance in treatment planning. CLINICAL SIGNIFICANCE: Maintaining ABH > 2 mm is essential for long-term implant stability, emphasizing early monitoring and bone preservation after LSFE.
Indexed as
Identifiers
42696071What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.